Predicting the course of fatty liver cirrhosis
Part of Digestive system, Hormones & metabolism clinical trials.
This study aims to build a tool to predict how MASLD-related cirrhosis (fatty liver disease leading to liver scarring) will progress. It may help doctors and patients better understand the outlook and plan care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You must have a cirrhosis diagnosis linked to fatty liver disease (MASLD-related cirrhosis).
- You must have at least one or two metabolic conditions like overweight, prediabetes, diabetes, or high blood pressure.
- You should not have heavy alcohol use in the past 5 years, and not drink more than 30g (men) or 20g (women) per day.
- Your liver problem must not be caused by other diseases like hepatitis B or C, autoimmune disease, or other liver conditions.
- You must not have had liver complications like fluid in the belly, bleeding from veins in the food pipe, or confusion from liver disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study aims to better classify a common type of fatty liver disease (called MAFLD) using liver biopsy samples. It may help researchers understand different subtypes of the disease and could lead to more personalized care.
This study tests a new screening tool to find advanced liver scarring in people with liver disease linked to diabetes. It helps doctors decide who needs more tests or specialist care.
This study uses routine blood tests to find people with advanced liver scarring caused by a condition called MASLD. If you are between 50 and 75, have certain metabolic risks, and get blood work from your primary care doctor at select centers, you may be eligible.
This study is testing whether advanced imaging and other non-invasive methods can properly identify people with significant liver scarring due to metabolic liver disease or alcohol-related liver disease. It may help find better ways to track liver health without repeated needle biopsies.
This study is testing whether an MRI can help doctors see liver scarring (fibrosis) in people with MASLD, a type of fatty liver disease. It is for patients who already need a liver biopsy as part of their care, to compare the MRI results with the biopsy.
This study uses digital twin technology (a computer model of your health) to improve early detection, personalized treatment, and long-term monitoring for people with liver disease. It includes different groups focusing on fatty liver disease, cirrhosis, and liver cancer, and aims to help doctors predict and manage complications like heart problems.
Hear when a new Metabolic Dysfunction-Associated Steatotic Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.